In contrast to the unconjugated mAb, the antibody-drug conjugate (CD6-ADC) selectively killed TCL cells in vitro and, more importantly, its systemic or local administration significantly reduced established TCL tumours in immunodeficient NSG mice. This evidence concerns the gene CD6 and neoplasm.